Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest update is out from Brainsway ( (BWAY) ).
On November 4, 2025, BrainsWay announced that the U.S. National Institutes of Health (NIH) awarded a $2.5 million grant to a research team led by Stanford University and the Palo Alto Veterans Institute for Research. The grant supports a clinical study evaluating the efficacy of an accelerated Deep TMS protocol using BrainsWay’s device for treating Alcohol Use Disorder (AUD). This study, which involves 100 adults in a randomized, double-blind trial, aims to explore the potential of high-intensity Deep TMS in reducing relapse risk and engaging targeted brain circuits. The announcement follows BrainsWay’s recent FDA clearance for its H1 Coil for treating major depressive disorder, highlighting the company’s ongoing advancements in neuromodulation techniques.
The most recent analyst rating on (BWAY) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on Brainsway stock, see the BWAY Stock Forecast page.
Spark’s Take on BWAY Stock
According to Spark, TipRanks’ AI Analyst, BWAY is a Outperform.
Brainsway’s strong financial performance and positive earnings call sentiment are the most significant factors driving the stock score. The technical analysis supports a bullish outlook, although the high P/E ratio suggests valuation concerns. The absence of corporate events and dividend yield slightly tempers the overall score.
To see Spark’s full report on BWAY stock, click here.
More about Brainsway
BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The company specializes in Deep Transcranial Magnetic Stimulation (Deep TMS) technology, which is FDA-cleared for major depressive disorder, obsessive-compulsive disorder, and smoking addiction. Founded in 2003, BrainsWay operates in the United States and Israel, focusing on increasing global awareness and access to its Deep TMS treatments.
Average Trading Volume: 72,323
Technical Sentiment Signal: Buy
Current Market Cap: $333.3M
For detailed information about BWAY stock, go to TipRanks’ Stock Analysis page.